60 results about "Cationic liposome" patented technology

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.

The invention belongs to the field of pharmaceutical preparations and cosmetics, and particularly relates to a cationic liposome containing plant extracts as well as a preparation method and application of the cationic liposome. The preparation method comprises the following steps: co-melting or dissolving a cacumen biotae extract, a ginger root extract, a ginseng root extract and a lipid component in a proper organic solvent system, concentrating, adding into a hydration medium, and homogenizing to prepare the cationic liposome containing the plant extract component. According to the invention, the lipid component is taken as a carrier, so that the transdermal performance and bioavailability of the three plant extracts and the active components contained in the three plant extracts can be improved, and the three plant extracts and the active components can penetrate through the cuticle of the skin to the greatest extent, so that the efficacy is effectively exerted.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The invention discloses a mannose modified liposome gel microsphere oral delivery system based on cations and application of the mannose modified liposome gel microsphere oral delivery system. The oral delivery system comprises a core layer and a wrapping layer, the core layer is mannose modified cationic liposome loaded with a mucous membrane adjuvant retinoic acid and an antigen, and the wrapping layer is sodium alginate gel vulcanized and modified by cysteine. The mannose modified cationic liposome is prepared by coupling mannose on the surface of the cationic liposome, and the cysteine modified sodium alginate gel is used for protecting antigens in the core layer from being eroded by gastric juice, enhancing the adhesiveness of a delivery system in the intestinal tract and prolonging the retention time of the delivery system in the intestinal tract; in addition, the R-MLip can be expanded and released under the environment that the pH of the intestinal tract is increased. The inside of the gel microsphere of the oral delivery system shows a regular net-shaped structure and has abundant holes and channels, and the oral delivery system shows a good prospect in the aspect of enhancing mucous membrane and systemic immunity and possibly becomes a potential substitute of a traditional attenuated live vaccine in the future.

The invention discloses a periodontal local drug delivery system with antioxidant, anti-inflammatory and antibacterial synergistic effects and a preparation method of the periodontal local drug delivery system, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: firstly, preparing an organic phase from DSPC, cholesterol, SA and resveratrol, and preparing a cationic liposome by taking PBS as a water phase; then preparing a water phase from AlgMA and LAP, taking a surfactant solution as an oil phase, and preparing polydopamine hydrogel microspheres through PDA surface modification; and finally, carrying out physical adsorption loading. Through the synergistic effect of the resveratrol, the cationic liposome and the polydopamine, a periodontitis pathological chain is comprehensively intervened, synergistic treatment is achieved, excellent antibacterial performance, anti-inflammatory effect and antioxidant effect are achieved, the retention rate of the medicine is increased, and the problems that traditional treatment medicine cannot achieve antibacterial, inflammation regulation and oxidative stress synergistic treatment at the same time, and the treatment effect is poor are solved. The residence time of the medicine in the periodontal pocket is short, and frequent administration is needed.

The invention discloses a photosensitizer, dynamic antibacterial hydrogel containing lipidosome wrapping the photosensitizer and a preparation method and application of the dynamic antibacterial hydrogel, and belongs to the technical field of biological materials. The invention provides a novel D-A-D type photosensitizer TPT which is simple in structure and simple in synthetic route, and from the angles of safety, practicability and use specificity of hydrogel dressing, modified hyaluronic acid and modified carboxymethyl chitosan are used as raw materials, cationic liposome wrapping the novel photosensitizer TPT is carried, and the hydrogel dressing is prepared. The efficient antibacterial dynamic cross-linked hydrogel material is prepared. The hydrogel disclosed by the invention has two pH response bonds, namely an imine bond and a boric acid ester bond, and has good moisture retention and biocompatibility; meanwhile, the hydrogel is loaded with the cationic liposome wrapping the novel photosensitizer TPT, so that the hydrogel has excellent active oxygen yield. The hydrogel disclosed by the invention aims to quickly resist bacteria, promote wound healing, reduce infection risk and improve the success rate of treatment through the targeted drug release function of the intelligent hydrogel.

The present invention relates to an mRNA vaccine composition for the prevention of enterovirus A71 (EV-A71) infection. The composition comprises an mRNA encoding the VP1 protein of EV-A71 and lipid nanoparticles (LNPs) comprising specific cationic lipids. Compared with the conventional cationic lipid system, the imidazopyridyl cationic lipid A5 with strong membrane fusion capability is adopted, so that obvious neutralizing antibody and cellular immune response can be induced under single-time and low-dose immune conditions, and excellent safety and children applicability are shown.

The invention discloses an immune agonist and a preparation method thereof, and relates to the technical field of immune agonist preparation, and the preparation method of the immune agonist comprises the following specific steps: S1, preparing a double-target immune agonist monomer; s2, preparing a cationic liposome inner core; s3, biomimetic cell membrane coating; and S4, finished product detection. According to the immune agonist and the preparation method thereof, in the preparation process, a continuous flow microreactor is used for two-step synthesis of a double-target monomer, a segmented precise temperature control mode is matched with microwave strengthening, the reaction period can be shortened, efficient entrapment of the agonist is achieved through a micro-reaction technology, and the problems that a traditional batch method is low in entrapment efficiency and uneven in particle size are solved; in addition, MDC cell membrane extraction is conducted through differential centrifugation, the integrity of the membrane is guaranteed, active targeting of a CD11c marker on the surface of the MDC cell membrane is achieved through a cell biomimetic membrane, and after lipidosome and membrane vesicles with the volume ratio being 3: 1 are fused, the in-vitro BMDC binding rate is increased compared with that of naked lipidosome.

The invention provides ROS (reactive oxygen species)-responsive cationic liposome-loaded tryptanthrin as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ROS response cationic liposome loaded tryptanthrin disclosed by the invention comprises an ROS response cationic liposome and tryptanthrin which is entrapped in the ROS response cationic liposome; the ROS response cationic liposome is prepared from the following raw materials: egg yolk lecithin, cholesterol, DSPE-TK-PEG (distearoyl phosphatidylcholine) and DOTAP (dioctyl phthalate). In view of significant increase of intestinal local active oxygen under the ECLS condition, the ROS-responsive cationic liposome is adopted to wrap tryptanthrin, so that tryptanthrin is selectively released in an intestinal injury area, whole body exposure is reduced, and meanwhile, the protection effect on the intestinal tract is enhanced.

The invention provides a nanoparticle penetrating cornea as well as a preparation method and application thereof. The nanoparticle comprises a cationic liposome G2-C14, an inner core formed by aliphatic polyester and an amphiphilic polymer, and a shell modified by polysaccharide, the hydrophobic drug and the siRNA are loaded in the inner core. According to the nano-particles provided by the invention, through polysaccharide surface modification, ocular surface adhesion and trans-epithelium transport capability are enhanced, multi-barrier penetration of the eye is realized, the nano-particles are effectively delivered to a focus area of posterior segment of the eye, the delivered siRNA targets to silence the expression of age-related macular degeneration pathogenic genes, and the hydrophobic drug removes active oxygen and inhibits release of inflammatory factors, so that the anti-aging effect of the nano-particles is improved. The focus thickness is synergistically reduced.

The invention discloses a multi-chamber vesicle as well as a preparation method and application thereof. Each multi-chamber vesicle is an anionic liposome, and a cavity of the anionic liposome contains a plurality of cationic liposomes and a buffer solution containing Mg < 2 + >. According to the preparation method of the multi-chamber vesicle, a special oil phase and a water phase with different charges are introduced, so that the multi-chamber vesicle in which a plurality of cationic liposomes are wrapped by a single anionic liposome is successfully prepared. The multi-chamber vesicle is good in biocompatibility, controllable in particle size and stable in mechanical property, and provides technical support for preparation of artificial cells and novel drug carriers in the future.

The invention discloses a si-TGM2-loaded macrophage targeting nano-material as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims at solving the problem that a macrophage targeting nano-drug for inhibiting severe acute pancreatitis aiming at a TGM2 target is lacked in the prior art. The technical key points of the invention are as follows: the si-TGM2-loaded macrophage targeting nano material is provided, the si-TGM2-loaded macrophage targeting nano material is a lactoferrin modified cationic lipid nucleic acid drug, and the cationic lipid nucleic acid drug is prepared by coating si-TGM2 as shown in SEQ.ID. NO.1 with a cationic liposome. The si-TGM2-loaded macrophage targeting nanometer material disclosed by the invention has a wide application prospect in preparation of an acute pancreatitis diagnostic kit and a medicine.

Provided are a method for preparing cationic liposomes by using a high-pressure emulsification device, cationic liposomes prepared by the method, and a cosmetic composition, a food composition and a pharmaceutical composition, comprising the cationic liposomes. According to the method for preparing cationic liposomes, toxic organic solvents are not employed and thus it is possible to produce liposomes safe for the skin at mass scale by using a high-pressure emulsification device. In addition, the cationic liposomes prepared by the above method have excellent formulation stability, and are positively charged, so that the skin absorption ability of active ingredients loaded therein may be enhanced. Therefore, the cationic liposomes can be used in cosmetics, foods, drugs, and the like.

The present invention provides a use of paclitaxel cationic liposomes in the manufacture of a medicament for treating terminal solid cancer, a use of paclitaxel cationic liposomes and a systemic therapeutic agent in the manufacture of a medicament for treating terminal solid cancer, and a method for treating terminal solid cancer, in which a therapeutically effective amount of paclitaxel cationic liposomes is administered to a patient with terminal solid cancer, or a therapeutically effective amount of paclitaxel cationic liposomes and a systemic therapeutic agent is administered to a patient with terminal solid cancer.

This invention discloses a basic amino acid-modified 3S-PCL, its preparation method, and its applications, relating to the field of biomedical technology. The structural formula of the basic amino acid-modified 3S-PCL is as follows: [Structure formula would be inserted here]; where R is a basic amino acid; m, m1, and m2 are all positive integers, and m, m1, and m2 ≥ 1. This invention designs and synthesizes a basic amino acid-modified three-armed polycaprolactone (3S-PCL) material, which exhibits good biocompatibility and can replace cationic liposomes for nucleic acid delivery via lipid nanoparticles. The preparation method of this basic amino acid-modified 3S-PCL material is simple and rapid, particularly suitable for industrial production. Lipid nanoparticles prepared using this basic amino acid-modified 3S-PCL material as a gene carrier can achieve highly efficient delivery of nucleic acid drugs.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

This invention discloses a cell preparation targeting bone metastatic tumor cells, its preparation method, and its application, belonging to the field of biomedical technology. The cell preparation comprises senescent neutrophils and drug-loaded cationic liposomes internalized within them. The cationic liposomes encapsulate a STING agonist and a pan-photokinase inhibitor. The preparation method includes: preparing drug-loaded liposomes using a thin-film dispersion-ultrasound method; obtaining senescent neutrophils through in vitro culture of extracted neutrophils; and preparing a senescent neutrophil preparation loaded with liposomes. This invention utilizes the natural bone marrow homing ability of senescent neutrophils to achieve precise targeting of bone metastatic tumor cells, and co-delivers two drugs through liposomes, simultaneously activating anti-tumor immunity and inducing tumor cell apoptosis / autophagy, synergistically treating bone metastases. This system has high drug loading capacity, good encapsulation efficiency, and sustained-release effect, and the preparation process is simple and controllable, providing a new strategy for the treatment of cancer bone metastases.

The application belongs to the technical field of pharmaceutical preparations, and discloses a nano-liposome with synergistic effect of double adjuvants and a preparation method and application thereof.The preparation method of the nano-liposome with synergistic effect of double adjuvants comprises the following steps: (1) mixing manganese chloride solution, cationic liposome, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine-polyethylene glycol, cholesterol and a solvent to react, and evaporating to obtain a lipid film; (2) mixing the lipid film, human unmethylated oligodeoxynucleotide and water to heat, and filtering to obtain the nano-liposome with synergistic effect of double adjuvants.The obtained nano-liposome with synergistic effect of double adjuvants has excellent sustained release property.The obtained nano-liposome with synergistic effect of double adjuvants has stable physicochemical properties after being prepared into a nano-liposome vaccine adjuvant, and is convenient to store and transport.

The invention relates to an anti-ARDS cationic liposome delivery system and application thereof, in particular to an anti-ARDS cationic liposome delivery system and application thereof. The sivelestat sodium carrier is composed of DOTAP, DSPC, polyethylene glycol and cholesterol, and can load two micro RNAs (miR125 and miR223) and a fat-soluble drug sivelestat sodium at the same time. Through TEM (transmission electron microscope detection), Western Blot, real-time fluorescent quantitative PCR and LPS-induced mouse ARDS model pharmacological experiments, it is proved that the material can play a better anti-inflammatory role, the treatment effect is remarkable, and the material has a very good development prospect.

The application discloses an engineered potent dendritic cell vaccine and a preparation method and application thereof, and utilizes a nano-scale antigen delivery mode to fuse tumor antigens with cationic liposomes, destroys the stability of a lysosome membrane by means of cationic liposome charge interaction, makes part of the antigens escape into a cytoplasm to be cross-presented through an MHC I pathway, gives the DCs the ability to activate a cellular immune response to resist tumors, on the other hand, gives the DCs T cell directivity through a synthetic immunology method, promotes the interaction and signal transmission of DC-T cells, and the combination of the two mechanisms can overcome the low response rate problem of the existing DC vaccine, and maximizes the anti-tumor immune response.

The application belongs to the technical field of biological medicine, and particularly relates to an N,N-dimethylethylene diamine-thiodiglycolic acid monocholesteryl ester conjugate as well as a preparation method and application thereof. The structural formula of the N,N-dimethylethylene diamine-thiodiglycolic acid monocholesteryl ester conjugate is as follows: first, cholesteryl and thiodiglycolic anhydride are dissolved together, N,N-dimethylaminopyridine is added, and a reflux reaction is performed to obtain thiodiglycolic acid monocholesteryl ester; then, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride is dissolved together, N,N-dimethylethylene diamine is added, and a reaction is performed to obtain a conjugate molecule. The conjugate is blended with lecithin to serve as a cationic liposome. By adjusting the ratio of lecithin and the conjugate, the particle size and potential of the cationic liposome can be adjusted.

The invention relates to an oral nano traditional Chinese medicine antigen delivery system as well as a construction method and application thereof, and belongs to the technical field of oral nano materials. The construction method comprises the following steps: (1) preparing an OM nanoparticle suspension; (2) preparing a cationic liposome suspension; (3) preparing an OM / BF loaded cationic liposome suspension; and (4) constructing an oral nano traditional Chinese medicine antigen delivery system. According to the invention, multiple barriers of gastrointestinal tracts are broken through, the bioavailability of drugs is improved, precise immune tracking is realized through an OVA tumor antigen model, and in-vivo anti-tumor CTL reaction is simulated, so that an anti-tumor effect is synergistically exerted on three levels of a cell level, a tissue level and an immune level; according to the preparation method, the problems of poor water solubility and low delivery efficiency of bufalin serving as a traditional Chinese medicine active ingredient are effectively solved, meanwhile, through macrophage-mediated immunoregulation and accurate drug release, the targeting property and the treatment efficiency are improved, and a new way is opened up for tumor immunotherapy of oral nano traditional Chinese medicines.

The present invention provides a use of a paclitaxel cationic liposome in preparation of a drug for treating advanced solid tumors, a use of the paclitaxel cationic liposome and a system therapeutic drug in preparation of a drug for treating advanced solid tumors, and a method for treating advanced solid tumors. A therapeutically effective amount of paclitaxel cationic liposome is administered to patients with advanced solid tumors, or a therapeutically effective amount of paclitaxel cationic liposome and system therapeutic drug is administered to patients with advanced solid tumors.

This invention belongs to the technical field of functional personal care products, and specifically relates to a highly efficient and stable natural sulfur hot spring bath concentrate formula and its preparation process. The bath concentrate formula, by mass percentage, comprises the following components: 35.0-65.0% sulfur hot spring active concentrate, 0.001-0.01% sodium selenite, 0.1-1.0% sodium thiosulfate, 0.05-0.2% disodium EDTA, 0.5-3.0% cationic liposomes, 0.2-0.8% carrageenan, 0.5-3.0% calcium source, 0.3-2.0% magnesium source, 0.1-0.5% bisabolol, 0.1-0.5% dipotassium glycyrrhizate, 0.2-1.5% citrate-sodium citrate buffer pair, 3.0-8.0% polyol, 0.1-0.3% β-cyclodextrin-encapsulated fragrance, and deionized water to 100%. A liquid bath concentrate was obtained using natural sulfur hot spring water as the water source, which fully retains its active sulfide spectrum and characteristic mineral ions, and can be stored for a long time at normal temperature and pressure. It has the advantages of high stability, high polysulfide content, slow release, and no irritation.

The present application relates to the technical field of hydrogel composite scaffold, in particular to a layer-by-layer self-assembled oxygen-responsive liposome hydrogel composite scaffold and a preparation method, hydrophilic nerve growth factor (GDNF) is encapsulated in the aqueous internal region of the liposome, and low-oxygen-responsive vascular endothelial growth factor (VEGF) plasmid and polyarginine are coated by electrostatic adsorption layer by layer (LBL), so as to construct an intelligent responsive LBL double-drug cationic liposome; subsequently, hyaluronic acid-carboxymethyl cellulose sodium (HA-CMC) hydrogel is introduced to carry the liposome to form a double-drug composite scaffold, so as to enhance the adhesion and local release characteristics of the composite scaffold on the wound surface. In a diabetic animal model, the LBL liposome loaded on the HA / CMC hydrogel can significantly accelerate wound healing, promote collagen deposition, angiogenesis and nerve fiber regeneration, and regulate the polarization of macrophages to the repair phenotype, thereby reducing the inflammatory response and achieving functional tissue repair.

The invention provides a peptide composition for skin care products and a preparation method of the peptide composition, and belongs to the technical field of cosmetics. The composition includes liposome-resin hybrid particles, a competitive cationic compound, and a gelling agent. The hybrid particle is formed by cation exchange resin and peptide-loaded cationic liposome through electrostatic interaction, a competitive cationic compound (such as choline chloride) can prevent competitive adsorption of other cations, and a gelling agent (such as ammonium acryloyldimethyl taurate / VP copolymer) forms a three-dimensional network structure to prevent particle sedimentation. According to the system, the physical and chemical stability of peptide components in a liquid formula is remarkably improved, transdermal absorption is promoted by utilizing lipidosome, and the system is suitable for anti-aging, barrier repairing and moisturizing skin care products.

The application discloses a nucleic acid-containing nano-carrier and a preparation method and application thereof, and relates to the technical field of nucleic acid delivery, and specifically discloses a nucleic acid-containing nano-carrier, which comprises a nucleic acid component, a cationic liposome and a stabilizer; the average particle size of the nucleic acid-containing nano-carrier is less than or equal to 400 nm; the Zeta potential of the nucleic acid-containing nano-carrier is-10 mV to-40 mV; and the binding rate of the nucleic acid component and the cationic liposome in the nucleic acid-containing nano-carrier is greater than or equal to 50%. The nucleic acid-containing nano-carrier can effectively load and deliver the nucleic acid component, and in practical application, the nucleic acid component can be guaranteed to have high permeability in the skin, and excellent effects such as low irritation and high stability can also be guaranteed.